📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Xcovery

1.1 - Company Overview

Xcovery Logo

Xcovery

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of low-toxicity, molecular-targeted oral cancer therapeutics, including Ensartinib for ALK-positive non-small cell lung cancer and Vorolanib, a VEGFR/PDGFR tyrosine kinase inhibitor for solid tumors such as renal cell carcinoma. Conducts clinical trials, seeks partnerships to launch Ensartinib globally and advance Vorolanib in combination therapy, and offers patient information and support resources.

Products and services

  • Ensartinib: A molecular-targeted oral therapy for ALK-positive non-small cell lung cancer, demonstrating effectiveness in patients with specific mutations and evaluated for efficacy and safety in clinical trials
  • Vorolanib: An oral tyrosine kinase inhibitor targeting VEGFR/PDGFR to treat solid tumors, including renal cell carcinoma, assessed in clinical studies and intended for combination therapy development
  • Clinical Trials: Trial-based studies rigorously evaluating Ensartinib and Vorolanib for efficacy and safety across various cancer types, including ALK-positive non-small cell lung cancer and renal cell carcinoma

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Xcovery

Theraclion Logo

Theraclion

HQ: France Website
  • Description: Provider of high-intensity focused ultrasound (HIFU) echotherapy medical equipment, combining HIFU with standard ultrasound for non-invasive treatment and target localization. Solutions include SONOVEIN for varicose veins; ECHOPULSE for thyroid nodules and breast fibroadenoma; CURE-OP for combinational cancer therapy integrating ultrasound with radiotherapy; and EPack single-use disposables for cooling and coupling.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Theraclion company profile →
Mainz Biomed Logo

Mainz Biomed

HQ: Germany Website
  • Description: Provider of molecular genetic diagnostic solutions for early cancer detection, including ColoAlert, a non-invasive at-home PCR-based colorectal cancer screening test; eAArly DETECT, a multimodal test combining FIT, mRNA biomarkers and AI to differentiate CRC, advanced and non-advanced adenomas; PancAlert, an early-stage pancreatic cancer screening test in development; and ReconAAsense, an FDA PMA pivotal study for next-gen colorectal screening approval.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Mainz Biomed company profile →
Biofidelity Logo

Biofidelity

HQ: United Kingdom Website
  • Description: Provider of molecular diagnostic assays and platforms for rapid detection of target DNA sequences and actionable genomic biomarkers, with applications in oncology, prenatal testing, and infectious disease. Products include ASPYRE-Lung for guideline-recommended lung cancer biomarkers with results in days, and ASPYRE, a chemistry platform usable on existing PCR instruments.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Biofidelity company profile →
IDEC Pharmaceuticals Logo

IDEC Pharmaceuticals

HQ: United States Website
  • Description: Provider of therapy development targeting neurodegenerative, hematologic, and autoimmune diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full IDEC Pharmaceuticals company profile →
Imvax Logo

Imvax

HQ: United States Website
  • Description: Provider of patient-specific vaccines and immunotherapies for solid tumors, including IGV-001, a personalized treatment for glioblastoma in Phase 2b trials, and preclinical programs IEC-001 (endometrial), IHC-001 (hepatocellular), IUC-001 (urothelial), and IOC-001 (ovarian). Offers the Goldspire platform to capture a tumor’s full antigen signature for developing personalized immunotherapies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Imvax company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Xcovery

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Xcovery

2.2 - Growth funds investing in similar companies to Xcovery

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Xcovery

4.2 - Public trading comparable groups for Xcovery

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Xcovery

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Xcovery

What does Xcovery do?

Xcovery is a provider of low-toxicity, molecular-targeted oral cancer therapeutics, including Ensartinib for ALK-positive non-small cell lung cancer and Vorolanib, a VEGFR/PDGFR tyrosine kinase inhibitor for solid tumors such as renal cell carcinoma. Conducts clinical trials, seeks partnerships to launch Ensartinib globally and advance Vorolanib in combination therapy, and offers patient information and support resources.

Who are Xcovery's competitors?

Xcovery's competitors and similar companies include Theraclion, Mainz Biomed, Biofidelity, IDEC Pharmaceuticals, and Imvax.

Where is Xcovery headquartered?

Xcovery is headquartered in United States.

How many employees does Xcovery have?

Xcovery has 1,000 employees 🔒.

When was Xcovery founded?

Xcovery was founded in 2010 🔒.

What sector and industry vertical is Xcovery in?

Xcovery is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Xcovery

Who are the top strategic acquirers in Xcovery's sector and industry

Top strategic M&A buyers and acquirers in Xcovery's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Xcovery?

Top strategic M&A buyers groups and sectors for Xcovery include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Xcovery's sector and industry vertical

Which are the top PE firms investing in Xcovery's sector and industry vertical?

Top PE firms investing in Xcovery's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Xcovery's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Xcovery's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Xcovery's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Xcovery include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Xcovery's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Xcovery?

The key public trading comparables and valuation benchmarks for Xcovery include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Xcovery for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Xcovery with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Xcovery's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Xcovery with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Xcovery's' sector and industry vertical?

Access recent funding rounds and capital raises in Xcovery's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Xcovery